Notice Regarding the Determination of Director Candidates and CEO Candidate

Process and Reasons for Determining Director Candidates and CEO Candidate

Toho Holdings, in preparation for the 78th Ordinary General Meeting of Shareholders scheduled for June 26, 2026, has determined the director candidates and CEO candidate based on the opinions of the Nomination and Remuneration Committee, which is majority composed of independent external directors. The committee conducted interviews with incumbents and evaluations by external experts, based on the director appointment criteria and CEO selection criteria established in December 2025. After evaluating six CEO candidates, it was judged that the reappointment of the current CEO, Hiromi Edahiro, is the best choice. Mr. Masahiko Ito is scheduled to be appointed as a new external director, possessing high independence and expected to strengthen the board's supervisory system.

List of Director Candidates and Executive Structure

The director candidates consist of four reappointments, one reappointed external director, and one new appointment. Among the directors who are audit and supervisory committee members, two are scheduled for reappointment, one is not up for election, and one is to retire. Mr. Shuzo Kono will be promoted and serve as director and senior managing executive officer, overseeing the dispensing pharmacy business and others. The executive structure clarifies the responsibilities centered on CEO Hiromi Edahiro and COO Akira Umada, including pharmaceutical wholesaling, manufacturing and sales, and transformation promotion. A skills matrix of directors was also disclosed, establishing a system with expertise covering overall management, finance and accounting, market, human resources and organizational development, legal and risk management, sales strategy, business development, and pharmaceutical administration and policy.